Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
| ▸ | GABRE | P78334 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2364943 | 0.86 | DHFR (0.47) | DHFRALDH1A1TLR8TLR7MEN1 | |
| SCHEMBL1025561 | 0.86 | DHFR (0.47) | DHFRALDH1A1TLR8TLR7MEN1 | |
| SCHEMBL2364340 | 0.77 | TLR8 (0.46) | DHFRTLR8TLR7 | |
| SCHEMBL4949768 | 0.77 | GPR84 (0.47) | DHFRALDH1A1MEN1KMT2AKCNH2 | |
| SCHEMBL10818337 | 0.75 | KMT2A (0.37) | DHFRALDH1A1MEN1KMT2AKCNH2 | |
| SCHEMBL10815973 | 0.75 | MEN1 (0.37) | ALDH1A1MEN1KMT2AKCNH2KDM4E | |
| SCHEMBL10816555 | 0.75 | MEN1 (0.37) | DHFRALDH1A1MEN1KMT2AKCNH2 | |
| SCHEMBL3265562 | 0.72 | MEN1 (0.39) | ALDH1A1MEN1KMT2AKCNH2KDM4E | |
| SCHEMBL17545030 | 0.72 | DHFR (0.54) | DHFRTLR8TLR7KDM4E | |
| SCHEMBL10858339 | 0.72 | MEN1 (0.35) | DHFRALDH1A1MEN1KMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700601-B2 | Substituted indazoles of formula 1.0 that are kinase inhibitors | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1871765-B1 | 3-(INDAZOL-5-YL)-(1,2,4)TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORP (US) | 2009-12-09 | — | — | EP | disclosed |
| US-7528132-B2 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; indazolyl [1,2,4]triazine compounds | SCHERING CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| EP-2001870-A2 | KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20080021019-A1 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; substituted pyrazine compounds | SCHERING CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080004257-A1 | Kinase inhibitors | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| WO-2007126964-A2 | KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-11-08 | — | — | WO | disclosed |
| EP-0088593-B1 | 1,2,4-TRIAZINE AND PYRAZINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1987-05-27 | — | — | EP | disclosed |
| US-4585861-A | ACTIVATORS OF GAMMA-AMINOBUTYRIC ACID AND BENZODIAZEPINE BINDING | ELI LILLY AND COMPANY (US) | 1986-04-29 | — | — | US | disclosed |
| US-4585861-A | ACTIVATORS OF GAMMA-AMINOBUTYRIC ACID AND BENZODIAZEPINE BINDING | ELI LILLY AND COMPANY (US) | 1986-04-29 | — | — | US | disclosed |
| US-4013654-A | ANTIINFLAMMATORY | ELI LILLY AND COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
| US-4008232-A | ANTIINFLAMMATORY | ELI LILLY AND COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
| US-4008232-A | ANTIINFLAMMATORY | ELI LILLY AND COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
| US-4008232-A | ANTIINFLAMMATORY | ELI LILLY AND COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
| US-3979516-A | Anti-inflammatory 3-amino-5,6-diaryl-1,2,4-triazines | ELI LILLY AND COMPANY (US) | 1976-09-07 | — | — | US | disclosed |
| US-3979516-A | Anti-inflammatory 3-amino-5,6-diaryl-1,2,4-triazines | ELI LILLY AND COMPANY (US) | 1976-09-07 | — | — | US | disclosed |
| US-3979516-A | Anti-inflammatory 3-amino-5,6-diaryl-1,2,4-triazines | ELI LILLY AND COMPANY (US) | 1976-09-07 | — | — | US | disclosed |
| US-3948894-A | ANTIINFLAMMATORY | ELI LILLY AND COMPANY (US) | 1976-04-06 | — | — | US | disclosed |
| US-3948894-A | ANTIINFLAMMATORY | ELI LILLY AND COMPANY (US) | 1976-04-06 | — | — | US | disclosed |
| US-3948894-A | ANTIINFLAMMATORY | ELI LILLY AND COMPANY (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004257-A1 | Kinase inhibitors | MAP3K1, MAP3K13, MAP3K6 | DHFR 2403/4885ALDH1A1 2101/4885TLR8 1031/4885 |
| US-20080021019-A1 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; substituted pyrazine compounds | BRCA1, PDK2, PDK1 | DHFR 651/4885ALDH1A1 550/4885TLR8 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.